Evidence map›Paper›PMID 38473245›Full record

ArticleCancers2024

High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia.

Lisa F Lincz, Danielle Z Theron, Daniel L Barry, Fiona E Scorgie, Jonathan Sillar, Opelo Sefhore, Anoop K Enjeti, Kathryn A Skelding

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Role of ENO1 and its targeted therapy in tumors.Journal of translational medicine · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lisa F LinczHaematology Department, Calvary Mater Newcastle, Waratah, NSW 2298, Australia.ORCID 0000-0002-1612-2382
Danielle Z TheronUniversity of Newcastle, University Drive, Callaghan, NSW 2308, Australia.
Daniel L BarryUniversity of Newcastle, University Drive, Callaghan, NSW 2308, Australia.
Fiona E ScorgieHaematology Department, Calvary Mater Newcastle, Waratah, NSW 2298, Australia.ORCID 0000-0002-2762-9883
Jonathan SillarHaematology Department, Calvary Mater Newcastle, Waratah, NSW 2298, Australia.
Opelo SefhoreHaematology Department, Calvary Mater Newcastle, Waratah, NSW 2298, Australia.
Anoop K EnjetiHaematology Department, Calvary Mater Newcastle, Waratah, NSW 2298, Australia.
Kathryn A SkeldingUniversity of Newcastle, University Drive, Callaghan, NSW 2308, Australia.ORCID 0000-0002-9230-3417
Hunter Medical Research Institute · AUJohn Hunter Hospital · AUUniversity of Newcastle Australia · AU

Funding

Jane Reid Harle Memorial Grant, Calvary Mater Newcastle n/aMargaret Mitchell Research Grant, Calvary Mater Newcastle n/aPrecision Medicine Group, Hunter Medical Research Institute n/aUniversity of Newcastle Strategic Research Pilot Grant n/a
6 · The paper itself

Abstract

In solid tumours, high expression of the glycolytic enzyme, α-enolase (ENO1), predicts for poor patient overall survival (OS), and circulating autoantibodies to ENO1 correlate positively with diagnosis and negatively with advanced disease. Although ENO1 is one of the most highly expressed genes in acute myeloid leukaemia (AML), its potential role as a biomarker in AML or its precursor, myelodysplastic neoplasms (MDS), has not been investigated. A meta-analysis of nine AML online datasets (n = 1419 patients) revealed that high ENO1 expression predicts for poor OS (HR = 1.22, 95% CI: 1.10-1.34,

Indexed as

acute myeloid leukaemiaalpha-enolaseautoantibodiesbiomarkerbone marrowENO1myelodysplastic neoplasms

Identifiers

PMID38473245
PMCPMC10931177
OpenAlexW4392101942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.